Initial Testing of Lenalidomide by the Pediatric Preclinical Testing Program

BACKGROUND: Lenalidomide, a novel immunomodulatory agent, is reported to modulate stem cell differentiation, and have direct antiproliferative activity as well as inhibit inflammation and hyperalgesia. On the basis of this varied pharmacological profile, lenalidomide is under investigation as a trea...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Pediatr Blood Cancer
Prif Awduron: Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Gorlick, Richard, Kolb, E. Anders, Lock, Richard, Maris, John M., Carol, Hernan, Morton, Christopher L., Billups, Catherine A., Smith, Malcolm A., Houghton, Peter J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2011
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4505747/
https://ncbi.nlm.nih.gov/pubmed/21360651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.22877
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg